title: Levosimendan as treatment option in severe verapamil intoxication: a case report and review of the literature.
abstract: Cardiovascular shock due to verapamil intoxication is often refractory to standard resuscitation methods. Recommended therapy includes prevention of further absorption of the drug, inotropic therapy, calcium gluconate, and hyperinsulinemia/euglycemia therapy. Often further measures are needed such as ventricular pacing or mechanical circulatory support. Still, mortality remains high. Levosimendan, an inotropic agent, that enhances myofilament response to calcium, increases myocardial contraction and could therefore be beneficial in verapamil intoxication. Here, we report the case of a 60-year-old patient with clinically severe verapamil poisoning who presented with shock, bradycardia, and sopor. Standard therapy including high-dose inotropes failed to ameliorate the signs of intoxication. But additional therapy with levosimendan led to rapid improvement. Based on this observation, the literature is reviewed focusing on utilization of levosimendan in the treatment of calcium channel blocker overdose. We suggest to consider levosimendan as additional treatment option in patients with cardiovascular shock due to verapamil intoxication that are refractory to standard management.
authors.affiliation: Medical Intensive Care Unit, University Hospital Basel, 4031 Basel, Switzerland.
authors.forename: Mirjam
authors.initials: M
authors.lastname: Osthoff
authors.forename: Christine
authors.initials: C
authors.lastname: Bernsmeier
authors.forename: Stephan C
authors.initials: SC
authors.lastname: Marsch
authors.forename: Patrick R
authors.initials: PR
authors.lastname: Hunziker
references.citation: Am J Med. 1993 Oct;95(4):431-8
references.pmid: 8213877
references.citation: J Crit Care. 2005 Mar;20(1):114-5
references.pmid: 16015526
references.citation: Anesth Analg. 2009 Mar;108(3):790-2
references.pmid: 19224785
references.citation: Drug Saf. 2003;26(2):65-79
references.pmid: 12534324
references.citation: J Cardiovasc Pharmacol. 1995;26 Suppl 1:S10-9
references.pmid: 8907127
references.citation: N Engl J Med. 2001 May 31;344(22):1721-2
references.pmid: 11386285
references.citation: J Emerg Med. 1991 Sep-Oct;9(5):357-66
references.pmid: 1940240
references.citation: Crit Care Med. 2008 Aug;36(8):2257-66
references.pmid: 18664782
references.citation: J Mol Cell Cardiol. 1995 Sep;27(9):1859-66
references.pmid: 8523447
references.citation: Ann Emerg Med. 1986 Oct;15(10):1221-4
references.pmid: 3752656
references.citation: Acta Anaesthesiol Scand. 2003 Sep;47(8):1038-40
references.pmid: 12904199
references.citation: J Toxicol Clin Toxicol. 1999;37(4):463-74
references.pmid: 10465243
references.citation: Resuscitation. 2003 May;57(2):211-3
references.pmid: 12745190
references.citation: Toxicol Appl Pharmacol. 1997 Aug;145(2):357-62
references.pmid: 9266809
references.citation: J Med Toxicol. 2009 Mar;5(1):3-7
references.pmid: 19191208
references.citation: J Cardiovasc Pharmacol. 2007 Sep;50(3):257-63
references.pmid: 17878752
references.citation: Am J Crit Care. 2007 Sep;16(5):498-503
references.pmid: 17724247
references.citation: Clin Toxicol (Phila). 2008 Jan;46(1):50-6
references.pmid: 17926153
references.citation: J Cardiovasc Pharmacol. 1995 May;25(5):794-801
references.pmid: 7630157
references.citation: Eur Heart J. 2002 Sep;23(18):1422-32
references.pmid: 12208222